GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Total Liabilities

Purple Biotech (XTAE:PPBT) Total Liabilities : ₪38.30 Mil (As of Dec. 2023)


View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Total Liabilities?

Purple Biotech's Total Liabilities for the quarter that ended in Dec. 2023 was ₪38.30 Mil.

Purple Biotech's quarterly Total Liabilities increased from Jun. 2023 (₪20.11 Mil) to Sep. 2023 (₪25.08 Mil) and increased from Sep. 2023 (₪25.08 Mil) to Dec. 2023 (₪38.30 Mil).

Purple Biotech's annual Total Liabilities increased from Dec. 2021 (₪19.49 Mil) to Dec. 2022 (₪28.80 Mil) and increased from Dec. 2022 (₪28.80 Mil) to Dec. 2023 (₪38.30 Mil).


Purple Biotech Total Liabilities Historical Data

The historical data trend for Purple Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Total Liabilities Chart

Purple Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.77 15.51 19.49 28.80 38.30

Purple Biotech Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.80 23.11 20.11 25.08 38.30

Purple Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Purple Biotech's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=27.496+(0.624+9.638
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.54)
=38.30

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=169.583-131.285
=38.30

Purple Biotech's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=27.496+(0.624+9.638
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.54)
=38.30

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=169.583-131.285
=38.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Purple Biotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Purple Biotech (XTAE:PPBT) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Purple Biotech (XTAE:PPBT) Headlines

From GuruFocus

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

By sperokesalga sperokesalga 03-24-2023

Purple Biotech Announces Executive Leadership Changes

By PurpleRose PurpleRose 07-14-2022